Business Context and Reporting Period
This Form 8-K Current Report was filed by Retractable Technologies, Inc. on April 27, 2004. The filing discloses a material event under Item 5 (Other Events and Regulation FD Disclosure) regarding the resolution of a patent infringement lawsuit.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only specific financial figure disclosed is a one-time settlement payment.
- Settlement Payment: $1,000,000.00 to be received from New Medical Technology (NMT) within three days of the Consent Judgment entry.
Material Changes
The primary material change is the settlement of the "Infringement Suit" filed on February 1, 2002, and consolidated with a second complaint filed on February 18, 2003. The lawsuit involved allegations of willful infringement of three patents (U.S. Patent Nos. 5,578,011; 6,090,077; and 5,385,551) related to syringes with retractable needles.
Key outcomes of the settlement include:
- Admission of Infringement: NMT admitted that the NMT Safety Syringe infringed the Asserted Patents, which were deemed valid and enforceable.
- Injunction: NMT is enjoined from importing, making, using, selling, or offering to sell the NMT Safety Syringe in the United States until the patents expire.
- Release of Claims: NMT released the Company and Thomas J. Shaw from claims asserted in the suit, while the Company released NMT from causes of action in the suit, subject to specific exclusions.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or general risk factors. However, the settlement agreement explicitly preserves the Company's right to pursue claims in the following areas:
- Claims against Becton Dickinson and Company or its affiliates.
- Claims against Abbott Laboratories or its affiliates.
- Claims regarding NMT's "Second Generation" syringe technology.
- Claims against other NMT medical products not covered by the NMT Safety Syringe.
- Claims against NMT in jurisdictions outside the United States.
Investor Verification Checklist
- Verify the receipt of the $1,000,000 settlement payment in the Company's next financial statement.
- Confirm the entry of the Stipulation and Consent Judgment in the United States District Court for the Eastern District of Texas.
- Monitor ongoing litigation or potential claims against Becton Dickinson, Abbott Laboratories, and NMT's "Second Generation" products.
- Review the press release issued on April 29, 2004, for additional public commentary on the settlement.